FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL        |           |  |  |  |  |  |  |  |  |  |
|---------------------|-----------|--|--|--|--|--|--|--|--|--|
| OMB Number:         | 3235-0287 |  |  |  |  |  |  |  |  |  |
| Estimated average I | hurden    |  |  |  |  |  |  |  |  |  |

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

|  |            |                |                                 |   | . ,   |   |      | <u> </u>                               |               |  |   |   |   |  |
|--|------------|----------------|---------------------------------|---|---|---|------|--|---------------|--|---|---|---|--|
| Name and Address of Reporting Person*     Bailey Sue |            |                |                                 |   | er Name <b>and</b> Ticke<br>egent BioSolu                   |   |      |  |               | ationship of Reporting Person(s) to lead applicable)  Director 10% ( |   |   |   |  |
| (Last) 2273 RESEARO                                  | (First)    | (Middle)       |                                 | 3. Date of Earliest Transaction (Month/Day/Year) 05/19/2011 |   |   |      |  |               |  | Officer (give title below)  | Other<br>below  | (specify<br>)                                       |  |
| (Street) ROCKVILLE (City)                            | MD (State) | 20850<br>(Zip) |                                 | 4. If Amendment, Date of Original Filed (Month/Day/Year)    |   |   |      |  |               | 6. Indi<br>Line)<br>X  | ′   |   |   |  |
|  |            | Table I - Nor  | n-Derivati                      | ive Se  | ecurities Acqu  | ıired,                                  | Disp | osed of, o                             | r Ben         | eficially  | Owned   |   |   |  |
| Date   |            |                | 2. Transaction Date (Month/Day/ |   | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 3.<br>Transaction<br>Code (Instr.<br>8) |      | 4. Securities a<br>Disposed Of (<br>5) |               |  | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership |  |
|  |            |                |                                 |   |   | Code                                    | v    | Amount                                 | (A) or<br>(D) | Price  | Transaction(s)<br>(Instr. 3 and 4)  |   | (Instr. 4)  |  |
| Common Stock <sup>(1)</sup> 05/19.                   |            |                |                                 |   |   | A                                       |      | 3,600(2)                               | Α             | \$0  | 7,200   | D   |   |  |

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | of    |     | 6. Date Exerc<br>Expiration Da<br>(Month/Day/\) | ate                | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|--|---|------------------------------|---|-------|-----|---|--------------------|--|--|---|--|--|--|
|   |   |  |   | Code                         | v | (A)   | (D) | Date<br>Exercisable                             | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of<br>Shares |   |  |  |  |
| Director<br>Stock<br>Option<br>(right to<br>buy)    | \$22.02   | 05/19/2011                                 |   | A                            |   | 7,200 |     | (3)   | 05/18/2021         | Common<br>Stock  | 7,200                                  | \$0   | 7,200  | D  |  |

### **Explanation of Responses:**

- 1. Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.
- 2. These restricted stock units vest in three equal annual installments beginning on the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
- 3. The option will vest in three equal installments on May 19, 2012, May 19, 2013 and May 19, 2014 or, if the Company's Annual Meeting of Stockholders occurs prior to such date for any year, on the day prior to such year's Annual Meeting of Stockholders.

#### Remarks:

/s/R. Don Elsey, attorney-infact 05/23/2011

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.